A detailed history of New Edge Wealth, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, New Edge Wealth, LLC holds 40,150 shares of VRTX stock, worth $18.7 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
40,150
Previous 38,912 3.18%
Holding current value
$18.7 Million
Previous $18.2 Million 2.38%
% of portfolio
0.35%
Previous 0.4%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$460.0 - $505.78 $569,480 - $626,155
1,238 Added 3.18%
40,150 $18.7 Million
Q2 2024

Aug 01, 2024

BUY
$392.81 - $485.53 $1.67 Million - $2.06 Million
4,245 Added 12.25%
38,912 $18.2 Million
Q1 2024

May 06, 2024

BUY
$407.69 - $446.08 $1.67 Million - $1.83 Million
4,095 Added 13.39%
34,667 $14.5 Million
Q4 2023

Jan 29, 2024

BUY
$343.0 - $410.68 $1.19 Million - $1.43 Million
3,478 Added 12.84%
30,572 $12.4 Million
Q3 2023

Nov 08, 2023

BUY
$338.18 - $362.46 $2.12 Million - $2.27 Million
6,275 Added 30.14%
27,094 $9.42 Million
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $64,770 - $72,493
206 Added 1.0%
20,819 $7.33 Million
Q1 2023

May 08, 2023

BUY
$283.23 - $323.1 $66,559 - $75,928
235 Added 1.15%
20,613 $6.49 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $4,857 - $5,465
17 Added 0.08%
20,378 $5.88 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $4.48 Million - $5 Million
16,361 Added 409.03%
20,361 $5.9 Million
Q2 2022

Aug 09, 2022

BUY
$234.96 - $292.55 $383,454 - $477,441
1,632 Added 68.92%
4,000 $1.13 Million
Q1 2022

May 10, 2022

BUY
$221.42 - $260.97 $524,322 - $617,976
2,368 New
2,368 $618,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track New Edge Wealth, LLC Portfolio

Follow New Edge Wealth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Wealth, LLC with notifications on news.